Zobrazeno 1 - 10
of 340
pro vyhledávání: ''
Autor:
Teresa Pecere, Enzo Di Iorio, Stefano Moro, Ignazio Castagliuolo, Luisa Santoro, Modesto Carli, Matteo Fassan, Giulia Bernabè, Maicol Bissaro, Eleonora Ponterio, Giorgio Palù
Publikováno v:
International Journal of Cancer
Aloe-emodin (1,8-dihydroxy-3-(hydroxymethyl)-anthraquinone), AE, is one of the active constituents of a number of plant species used in traditional medicine. We have previously identified, for the first time, AE as a new antitumor agent and shown tha
Autor:
Marjolein J.E. Greuter, Felice N. van Erning, Cornelis J A Punt, Gabrielle Jongeneel, Geraldine R. Vink, Jos W. R. Twisk, Veerle M.H. Coupé, Miriam Koopman
Publikováno v:
International Journal of Cancer
International Journal of Cancer, 148(11), 2702-2711. Wiley-Liss Inc.
International journal of cancer. Journal international du cancer, 148(11), 2702-2711. Wiley-Liss Inc.
Jongeneel, G, Greuter, M J E, van Erning, F N, Twisk, J W R, Koopman, M, Punt, C J A, Vink, G R & Coupé, V M H 2021, ' Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients : A prospective cohort study ', International Journal of Cancer, vol. 148, no. 11, pp. 2702-2711 . https://doi.org/10.1002/ijc.33472
International Journal of Cancer, 148(11), 2702-2711. Wiley-Liss Inc.
International journal of cancer. Journal international du cancer, 148(11), 2702-2711. Wiley-Liss Inc.
Jongeneel, G, Greuter, M J E, van Erning, F N, Twisk, J W R, Koopman, M, Punt, C J A, Vink, G R & Coupé, V M H 2021, ' Longitudinal effects of adjuvant chemotherapy and related neuropathy on health utility in stage II and III colon cancer patients : A prospective cohort study ', International Journal of Cancer, vol. 148, no. 11, pp. 2702-2711 . https://doi.org/10.1002/ijc.33472
Patient's quality of life should be included in clinical decision making regarding the administration of adjuvant chemotherapy (ACT) in stage II/III colon cancer. Therefore, quality of life, summarized as health utility (HU), was evaluated for patien
Autor:
Bianca J. Kuhn, Claudia Lohrey, Felix Hoppe-Seyler, Tobias D. Strobel, Karin Hoppe-Seyler, Jeroen Krijgsveld, Julia Bulkescher, Antonia Däschle, Anja L. Herrmann
Publikováno v:
International Journal of Cancer. 149:1137-1149
Oncogenic types of human papillomaviruses (HPVs) are major human carcinogens. The viral E6/E7 oncogenes maintain the malignant growth of HPV-positive cancer cells. Targeted E6/E7 inhibition results in efficient induction of cellular senescence, which
Autor:
Viktor Umansky, Juliane Poelchen, Jochen Utikal, Karol Granados, Marlene Vierthaler, Laura Hüser, Tamara Steinfass, Qian Sun, Huizi Wu, Ke Liu, Aniello Federico, Daniel Novak
Publikováno v:
International Journal of Cancer. 149:657-674
Metastatic melanoma is an aggressive skin cancer and associated with a poor prognosis. In clinical terms, targeted therapy is one of the most important treatments for patients with BRAFV600E -mutated advanced melanoma. However, the development of res
Autor:
Satoru Kikuchi, Hiroshi Tazawa, Toshiaki Ohara, Yasuhiro Shirakawa, Kazuhiro Noma, Hiroaki Sato, Toru Narusaka, Takuya Kato, Akihiro Matsukawa, Toshiyoshi Fujiwara, Yuki Katsura, Noriyuki Nishiwaki, Yasuko Tomono
Publikováno v:
International Journal of Cancer. 149:347-357
Esophageal cancer is a disease showing poor prognosis. Although combination chemotherapy using cisplatin (CDDP) and 5-fluorouracil is standard for unresectable esophageal cancer, the response rate is 35%. Cancer stem cells (CSCs) and inflammation are
Autor:
Kyriakos P. Papadopoulos, David Ferry, Manuel Afable, Nizar M. Tannir, Alexandra Drakaki, Annie Hung, Jong Seok Kim, Johanna C. Bendell, Raid Aljumaily, Deborah J. Wong, Aung Naing
Publikováno v:
International Journal of Cancer. 149:403-408
Interleukin (IL)-10 has anti-inflammatory and CD8+ T-cell-stimulating properties. Pegilodecakin (pegylated recombinant human IL-10) induces intratumoral antigen-specific CD8 + T-cells and upregulates IFNγ and major histocompatibility complexes (MHC)
Autor:
Srikanth R. Polusani, Hongxin Fan, Marsha C. Kinney, Javier Esparza, Huynh Nga Nguyen, Matthew James Butler, Samy L. Habib, Gopalrao V.N. Velagaleti, Edward A. Medina, Valerie Cortez, Babatunde O. Oyajobi, Reto Asmis
Publikováno v:
Int J Cancer
Proteasome inhibitor (PI) therapy has improved the survival of multiple myeloma (MM) patients. However, inevitably, primary or acquired resistance to PIs leads to disease progression; resistance mechanisms are unclear. Obesity is a risk factor for MM
Autor:
Huili Wang, Loren S. Michel, Richard J. Wong, Vatche Tchekmedyian, Daphna Y. Gelblum, Lara Dunn, Alisa Rybkin, Bhuvanesh Singh, Kenneth K.-S. Ng, Jung Julie Kang, Wanqing Iris Zhi, Marc Cohen, Snehal G. Patel, C. Jillian Tsai, Juliana Eng, Ian Ganly, James Vincent Fetten, Nader Mohammed, Eric J. Sherman, Stephanie Lobaugh, Yao Yu, Alan L. Ho, Luc G. T. Morris, David G. Pfister, Jay O. Boyle, Sean McBride, Anna Lee, Jennifer R. Cracchiolo, Nancy Y. Lee, Ming Fan, Zhigang Zhang, S. Kitpanit, Kaveh Zakeri, Linda Chen, Nadeem Riaz
Publikováno v:
Int J Cancer
High-dose (HD) cisplatin remains the standard of care with chemoradiation for locally advanced oropharyngeal cancer (OPC). Cooperative group trials mandate bolus-HD (100 mg/m2 × 1 day, every 3 weeks) cisplatin administration at the beginning of the
Autor:
Dorte Linnemann, Julia S. Johansen, Kristin Skougaard, Dorte Nielsen, Jakob V. Schou, Mette Karen Yilmaz, Per Pfeiffer, Finn Ole Larsen, Benny V. Jensen, Estrid Høgdall, Helle Hjorth Johannesen
Publikováno v:
International Journal of Cancer. 148:2542-2556
Metastatic colorectal cancer (mCRC) is treated with cetuximab 250 mg/m2 administered weekly over 1 hour or biweekly (q2w) over 3.5 hours when combined with irinotecan. This prospective study investigated cetuximab 500 mg/m2 plus irinotecan 180 mg/m2
Autor:
Rachel Zamostiano, Hamutal Ben-Dov, Ayala Raanan, Eran Bacharach, Hanna Saleem, Marcelo Ehrlich, Rinat Semyatich, Sarah Dellac, Isaac P. Witz, Sara Lavi
Publikováno v:
International Journal of Cancer. 148:2321-2334
STAT1 is a critical effector and a target gene of interferon (IFN) signaling, and thus a central mediator of antiviral responses. As both a mediator and a target of IFN signals, STAT1 expression reports on, and determines IFN activity. Gene expressio